We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.15B
AUM Growth
-$403M
Cap. Flow
-$229M
Cap. Flow %
-3.73%
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
64
Reduced
62
Closed
12

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$35.2M
2
SYK icon
Stryker
SYK
+$32.7M
3
UNH icon
UnitedHealth
UNH
+$27.9M
4
PODD icon
Insulet
PODD
+$25.5M
5
RMD icon
ResMed
RMD
+$25.5M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$56.7M
2
ARGX icon
argenx
ARGX
+$45.6M
3
INSM icon
Insmed
INSM
+$43.4M
4
BSX icon
Boston Scientific
BSX
+$42.4M
5
HUM icon
Humana
HUM
+$36.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Industrials 0.05%
3 Communication Services 0.02%
4 Technology 0.02%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GMED icon
51
Globus Medical
GMED
$10.5B
$34.1M 0.55%
497,293
-82,605
-14% -$4.94M
REGN icon
52
Regeneron Pharmaceuticals
REGN
$70.9B
$33.9M 0.55%
32,297
+25,220
+356% +$24.4M
CRSP icon
53
CRISPR Therapeutics
CRSP
$4.71B
$33.4M 0.54%
617,649
-2,301
-0.4% -$133K
BEAM icon
54
Beam Therapeutics
BEAM
$2.83B
$33.2M 0.54%
1,418,121
+225,000
+19% +$5.53M
EVH icon
55
Evolent Health
EVH
$654M
$31.9M 0.52%
1,669,835
+186,739
+13% +$4.77M
VEEV icon
56
Veeva Systems
VEEV
$31.7B
$30.9M 0.5%
168,583
+336
+0.2% +$66.7K
TMDX icon
57
Transmedics
TMDX
$2.56B
$30.3M 0.49%
201,415
-162,649
-45% -$19.5M
RMD icon
58
ResMed
RMD
$28.9B
$29.8M 0.48%
155,881
+125,490
+413% +$25.5M
CNC icon
59
Centene
CNC
$32.8B
$27.9M 0.45%
421,458
+58,358
+16% +$4.24M
MCK icon
60
McKesson
MCK
$98.5B
$26.9M 0.44%
46,142
+37,145
+413% +$20.7M
CSTL icon
61
Castle Biosciences
CSTL
$733M
$26.5M 0.43%
1,217,101
-2,984
-0.2% -$66.5K
EWTX icon
62
Edgewise Therapeutics
EWTX
$4.28B
$25.7M 0.42%
+1,428,929
New +$24.9M
ANNX icon
63
Annexon
ANNX
$950M
$25.3M 0.41%
5,157,290
+2,975,000
+136% +$15.4M
TMO icon
64
Thermo Fisher Scientific
TMO
$198B
$23.6M 0.38%
42,626
+2,670
+7% +$1.53M
NTRA icon
65
Natera
NTRA
$38.9B
$23.2M 0.38%
213,987
-55,845
-21% -$5.67M
SILK
66
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$23.1M 0.38%
855,293
-662,937
-44% -$13.8M
MOH icon
67
Molina Healthcare
MOH
$11.7B
$22.7M 0.37%
76,393
-23,490
-24% -$7.97M
ESPR
68
DELISTED
Esperion Therapeutics
ESPR
$22.1M 0.36%
9,944,064
– –
GPCR icon
69
Structure Therapeutics
GPCR
$3.45B
$21.9M 0.36%
557,321
+193,395
+53% +$7.94M
DHR icon
70
Danaher
DHR
$144B
$21M 0.34%
83,920
-2,312
-3% -$584K
WVE icon
71
Wave Life Sciences
WVE
$1.12B
$20.4M 0.33%
4,094,458
– –
COR icon
72
Cencora
COR
$59.9B
$20.1M 0.33%
89,329
-42,175
-32% -$9.77M
STE icon
73
Steris
STE
$21.2B
$20M 0.33%
91,282
+17,848
+24% +$3.88M
HCM icon
74
HUTCHMED
HCM
$1.86B
$19.7M 0.32%
1,149,157
-5,475
-0.5% -$101K
IQV icon
75
IQVIA
IQV
$34.4B
$19.5M 0.32%
92,083
+83,747
+1,005% +$19M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2024 Portfolio in Review

As of Q2 2024, Bellevue Group held 178 positions worth $6.15B, down 6.1% from $6.56B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $229M in Q2 2024, closing 12 positions and reducing 62 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $34.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Edgewise Therapeutics worth $25.7M.

  • Bellevue Group's largest Q2 2024 buy was Edgewise Therapeutics: 1,428,929 shares worth $25.7M.
  • Bellevue Group added most to Biohaven in Q2 2024, an estimated $35.2M increase.
  • Bellevue Group's biggest Q2 2024 reduction was Intuitive Surgical, cutting an estimated $56.7M.
  • Bellevue Group fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $34.4M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.15B portfolio in Q2 2024.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2024.
  • Bellevue Group's portfolio value fell 6.1% quarter-over-quarter to $6.15B.

Based on Bellevue Group's 13F filing for Q2 2024, filed 14 Aug 2024.